BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9808499)

  • 1. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function.
    Pescovitz MD; Pruett TL; Gonwa T; Brook B; McGory R; Wicker K; Griffy K; Robinson CA; Jung D
    Transplantation; 1998 Oct; 66(8):1104-7. PubMed ID: 9808499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
    Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
    Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study.
    Pescovitz MD; Brook B; Jindal RM; Leapman SB; Milgrom ML; Filo RS
    Clin Transplant; 1997 Dec; 11(6):613-7. PubMed ID: 9408695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ganciclovir in pediatric renal transplant recipients.
    Zhang D; Lapeyraque AL; Popon M; Loirat C; Jacqz-Aigrain E
    Pediatr Nephrol; 2003 Sep; 18(9):943-8. PubMed ID: 12883977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics.
    Filler G; Lampe D; von Bredow MA; Lappenberg-Pelzer M; Rocher S; Strehlau J; Ehrich JH
    Pediatr Nephrol; 1998 Jan; 12(1):6-9. PubMed ID: 9502557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
    Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
    Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients.
    Anderson RD; Griffy KG; Jung D; Dorr A; Hulse JD; Smith RB
    Clin Ther; 1995; 17(3):425-32. PubMed ID: 7585846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients.
    Rui WB; An HM; Shao K; Zhai XH; Lu JQ; Hu SS; Chen B; Zhou PJ
    Eur J Clin Pharmacol; 2019 May; 75(5):677-686. PubMed ID: 30643927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients.
    Fishman JA; Doran MT; Volpicelli SA; Cosimi AB; Flood JG; Rubin RH
    Transplantation; 2000 Feb; 69(3):389-94. PubMed ID: 10706048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients.
    Chamberlain CE; Penzak SR; Alfaro RM; Wesley R; Daniels CE; Hale D; Kirk AD; Mannon RB
    Am J Transplant; 2008 Jun; 8(6):1297-302. PubMed ID: 18444933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of pharmacokinetics and safety of valganciclovir oral suspension treatment in pediatric kidney graft recipients--preliminary report].
    Rubik J; Kozłowski K; Grenda R; Prokurat S
    Przegl Lek; 2006; 63 Suppl 3():184-6. PubMed ID: 16898525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
    Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
    Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Safety of Valganciclovir in Pediatric Heart Transplant Recipients 4 Months of Age and Younger.
    Bradley D; Moreira S; Subramoney V; Chin C; Ives J; Wang K;
    Pediatr Infect Dis J; 2016 Dec; 35(12):1324-1328. PubMed ID: 27580058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood.
    Baldanti F; Simoncini L; Sarasini A; Zavattoni M; Grossi P; Revello MG; Gerna G
    Transplantation; 1998 Aug; 66(3):324-9. PubMed ID: 9721800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
    Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP;
    Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM; Lake KD; Arenas JD; Fontana RJ
    Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
    Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
    Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
    Ju HY; Kang HJ; Hong CR; Lee JW; Kim H; Park KD; Shin HY; Park JD; Choi EH; Lee HJ; Ahn HS
    Transpl Infect Dis; 2016 Jun; 18(3):396-404. PubMed ID: 27041364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis.
    Snell GI; Kotsimbos TC; Levvey BJ; Skiba M; Rutherford DM; Kong DC; Williams TJ; Krum H
    J Antimicrob Chemother; 2000 Apr; 45(4):511-6. PubMed ID: 10747829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistant Cytomegalovirus Infection After Renal Transplantation: Literature Review.
    Cintra-Cabrera M; Suárez-Benjumea A; Bernal-Blanco G; González-Roncero FM; Toapanta-Gaibor NG; Súñer-Poblet M; Pérez-Valdivia MÁ; Fernández-Cuenca F; Gentil-Govantes MÁ; Rocha-Castilla JL
    Transplant Proc; 2018 Mar; 50(2):575-577. PubMed ID: 29579856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.